1 |
Agresti A (1981). Measures of nominal-ordinal association, Journal of the American Statistical Association, 76, 524-529.
DOI
|
2 |
Chen C, Tsou H, Hsiao C, Lai Y, Chang W, and Liu J (2017). A tolerance interval approach to assessing the biosimilarity of follow-on biologics, Statistics in Biopharmaceutical Research, 9, 286-292.
DOI
|
3 |
Doll R and Pygott F (1952). Factors influencing the rate of healing of gastric ulcers admission to hospital, phenobarbitone, and ascorbic acid, Lancet, 259, 171-175.
DOI
|
4 |
Kang SH and Chow SC (2013). Statistical assessment of biosimilarity based on relative distance between follow-on biologics, Statistics in Medicine, 32, 382-392.
DOI
|
5 |
Kang SH and Kim Y (2014). Sample size calculations for the development of biosimilar products, Journal of Biopharmaceutical Statistics, 24, 1215-1224.
DOI
|
6 |
Kang SH, Jung J, and Baik S (2015). Sample size calculations for the development of biosimilar products based on binary endpoints, Communications for Statistical Applications and Methods, 22, 389-399.
DOI
|
7 |
Kang SH and Shin W (2015). Statistical assesment of biosimilarity based on the relative distance between follow-on biologics in the (k + 1)-arm parallel design, Communications for Statistical Applications and Methods, 22, 605-613.
DOI
|
8 |
Lawless JF (1982). Statistical Models and Methods for Lifetime Data, Wiley, New York.
|
9 |
Lu Y, Zhang Z, and Chow SC (2014). Frequency estimator for assessing of follow-on biologics, Journal of Biopharmaceutical Statistics, 24, 1280-1297.
DOI
|
10 |
Piccarreta R (2001). A new measure of nominal-ordinal association, Journal of Applied Statistics, 28, 107-120.
DOI
|
11 |
Roozenbeek B, Lingsma H, Perel P, Edwards P, Roberts I, Murray G, Maas A, and Steyerberg E (2011). The added value of ordinal analysis in clinical trials: an example in traumatic brain injury, Critical Care, 15, R127.
DOI
|
12 |
Shin W and Kang SH (2016). Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints, Journal of Biopharmaceutical Statistics, 26, 227-239.
DOI
|
13 |
Yang J, Zhang N, Chow SC, and Chi E (2012). An adapted F-test for homogeneity of variability in follow-on biological products, Statistics in Medicine, 32, 415-423.
DOI
|
14 |
Sankey S andWeissfeld L (1998). A study of the effect of dichotomizing ordinal data upon modeling, Communications in Statistics-Simulation and Computation, 27, 871-887.
DOI
|
15 |
US Food and Drug Administration (2015). Scientific consideration in demonstrating biosimilarity to a reference product: guidance for industry, Retrieved April, 2015, from: https://www.fda.gov/media/82647/download
|
16 |
Vulto A and Jaquez O (2017). The process defines the product: what really matters in biosimilar design and production?, Rheumatology, 56, iv14-29.
DOI
|
17 |
Zhang N, Yang J, Chow SC, and Chi E (2014). Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics, Journal of Biopharmaceutical Statistics, 24, 1239-1253.
DOI
|